

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Arbogast et al. Confirmation No.: 6754  
Serial No.: 10/661,032  
Filing Date: September 11, 2003  
Examiner: To be assigned  
Group Art Unit: 1616  
For: MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND  
DIAGNOSTIC APPLICATIONS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 7, 2005.

Signature: \_\_\_\_\_

Carrie L. Caggiano

**INFORMATION DISCLOSURE STATEMENT**

Sir:


Applicants respectfully submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in order to comply with the duty of disclosure under 37 C.F.R. § 1.56. These references are listed on the attached modified PTO Form No. 1449. A copy of each of the listed references are enclosed for the convenience of the Examiner.


This Information Disclosure Statement is being mailed before the mailing date of the first Office Action on the merits, and thus, pursuant to 37 C.F.R. § 1.97(b), Applicants respectfully request that the information be expressly considered during the prosecution of this application and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Applicants further request that a copy of the PTO Form No. 1449, appropriately initialed by the Examiner, be returned to Applicants' attorneys.

It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Director is authorized to charge Deposit Account No. 50-0540 for such fees. Early and favorable action is earnestly solicited.

Dated: January 7, 2005

Respectfully submitted,

  
Donald Rhoads, Reg. No. 34,705  
Rachel J. Lin, Reg. No. 51,098  
KRAMER LEVIN NAFTALIS & FRANKEL LLP  
919 Third Avenue  
New York, New York 10022  
(212) 715-9249 (phone)  
(212) 715-8000 (fax)

Based on Form PTO-1449 (3 90)				ATTY. DOCKET NO. 57637/1185		SERIAL NO. 10/661,032	
<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)				<b>APPLICANTS</b> Arbogast et al.			
				<b>FILING DATE</b> September 11, 2003		<b>GROUP ART UNIT</b> 1616	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	BA						
	BB						
<b>OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	CA	International Search Report for PCT/US03/28838, mailed October 12, 2004.					
	CB	Lu, D. et al. "Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies", <i>J. Biol. Chem.</i> , May 2000, Vol. 275, No. 19, pp. 14321-14330.					
	CC	Tamura, S. et al. "Expression and Function of c-Met, a Receptor for Hepatocyte Growth Factor, During T-Cell Development", <i>Scand. J. Immunol.</i> 1998, Vol. 47, pp. 296-301.					
	CD	Wei, K. et al. "Quantification of Renal Blood Flow With Contrast-Enhanced Ultrasound" <i>J. Am. Coll. Cardiol.</i> 2001, Vol. 37, No. 4, pp. 1135-40.					
	CE						
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			
* <b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							